Introduction
In patients with chronic viral hepatitis (CVH) liver biopsy has more important role in treatment planning than diagnostics. Nowadays, the role of liver needle biopsies is to provide a qualitative rather than a quantitative assessment of effects of viral hepatitis. For this qualitative assessment three scoring systems (Modified Knodell, METAVIR, Scheuer) are more widely used 1 Zone 3 necrosis + occasional portal-central (P-C) bridging 4
Zone 3 necrosis + multiple P-C bridging 5
Panacinar or multiacinar necrosis 6 C) Focal ("spotty") lytic necrosis, apoptosis, and focal inflammation 
No fibrosis 0
Fibrous expansion of some portal areas, with or without short fibrous septa 1
Fibrous expansion of most portal areas, with or without short fibrous septa 2
Fibrous expansion of most portal areas with occasional portal to portal (P-P) bridging 3
Fibrous expansion of portal areas with marked bridging (portal to portal (P-P) as well as portal to central (P-C) 4
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) 5
Cirrhosis, probable or definite 6
Maximum fibrosis score 6
Additional features which should be noted but not scored: Bile-duct inflammation and damage, lymphoid follicles, steatosis (mild, moderate or marked), Hepatocellular dysplasia (large-or small-cell), adenomatous hyperplasia, iron or copper overload, intracellular inclusions (eg. PAS-positive globules, Mallory bodies).
Immunohistochemical findings: Information on viral antigens, lymphocyte subsets or other features, when available, should be recorded and may be semi-quantitatively expressed. Table 4 . Algorithm for evaluation histological activity (METAVIR) meaning, reproducibility of these parameters vary in different scoring systems. In addition, there are difficulties in determining the cut-off values of these parameters for treatment decision making in our country. These problems often encountered in our daily practice, raise the need to examine the role of scoring systems in treatment decision making. In this study, the different scoring systems in chronic hepatitis B (CHB) are investigated in order to predict treatment outcome and to assess the importance of histological parameters in treatment decision making.
Material and Method

Patient Selection
Retrospectively reported liver needle biopsies in Hacettepe University, Faculty of Medicine, Department of Pathology between the years 2005-2009 were identified from database of our hospital. Patients with a complete clinical data and clinical follow up for at least 1 year, and to whom therapy has been started after biopsy were included in the study. There is no unique scoring system for CHB. Antiviral therapy choice for further classify the patients according to receiving the single antiviral agent. However, patient follow ups and determination of HBV DNA levels were performed and recorded according to current guidelines.
For statistical analysis Statistical Package for the Social Sciences (SPSS) software, version 17.0 (SPSS, Chicago, Illinois, USA) was used. Univariate analysis has been done.
Results
Patients' Characteristics
There were 32 female and 69 male patients. Median age was 38.1 (min: 18, max: 67). 71 of 101 cases (% 70.3) comply with the success criteria and 30 cases (% 29.7) do not. The distribution of patients according to the compliance of treatment success criteria are given in Table 5 .
Scoring systems: Findings Related to Necroinflammatory Activity
We have encountered no confluent necrosis among the patients with CHB according to Modified Knodell scoring system. Therefore, in statistical studies total HAI score was reduced from 18 to 12. There was no statistically significant relationship between total HAI score and treatment success (p >0.05) ( Table 6 ). The contribution of three parameters (interface hepatitis, lobular activity, portal inflammation) of this scoring system to the treatment response was also not statistically significant (p >0.05) ( Table 6 ).
The relationship between total METAVIR grade and treatment response was statistically significant (p = 0.008). To study this result, two parameters constituting total METAVIR histological activity grade (interface hepatitis and lobular activity) and treatment response were analyzed separately. There was significant relation between higher lobular activity and higher treatment success (p = 0.005) ( Table 7 ).
There were no statistically significant relation between the parameters of Scheuer`s scoring system which is taken up as third scoring system and treatment (portal inflammation in all cases p=0.36 and lobular activity p = 0.732) ( Table 8) .
Scoring Systems: Findings Related to Staging
There was no statistical relation between treatment success and degree of fibrosis in any of the scoring systems used (METAVIR, Modified Knodell and Scheuer scoring system) (p > 0.05).
CHB was nucleoside or nucleotide analogues and any interferon therapy was excluded in these patients to get a homogenous group.
Clinicopathological criteria were definite, adequacy of biopsy for evaluation, i.e. a minimum of 1.5 cm and a minimum of six tracts 4 , absence of medication intake and/or absence of secondary diseases (multiple myeloma, malignancies, lymphoproliferative diseases, inflammatory bowel disease, rheumatoid arthritis etc.) treatment outcomes of which can affect liver biopsy evaluation. Combined infection of HBV+HDV or HBV+HCV infections were excluded in the study group.
9 patients with CHB with a clinical follow-up prior to 2005 attuned to criteria were also included to this study. As a result, 101 CHB providing full compliance with these criteria are included to the study.
Histopathological Assessment
Five micron sections made after average 24 hours fixation in 10% formalin, processing and paraffin embedding, were examined by H-E, trichrome, Prussian blue and Gomori methenamine silver (reticulin) stains. In this study, Modified Knodell, METAVIR, Scheuer's scoring systems were used by one pathologist (SA) appropriately for both grading (the evaluation of hepatocellular damage and necroinflammatory changes) and staging (degree of fibrosis).
Patients with cirrhosis (Modified Knodell score 6 and METAVIR/Scheuer score 4) were not included in this study. For this reason statistical evaluation of staging depended on 0-5 points in Modified Knodell classification and 0-3 points in METAVIR/Scheuer classification.
Criteria for Treatment Success
Patients were divided into two groups (successful and unsuccessful) according to the compliance for the success criteria based according to accepted international and national guidelines 5, 6 . Goal of antiviral therapy in HBeAg-negative CHB is the reduction or extinction of HBV-DNA value, which is defined as virological response and normalization of aminotransferase levels is defined as biochemical response. Success in CHB treatment was defined as virological, biochemical and, if any, histological response after 48 weeks of therapy. Partial response, viral and biochemical breakthrough under antiviral therapy were classified as unsuccessful treatment response. Because of the different antiviral agents, it was not possible to thought as apoptosis rather than lytic necrosis 12 . So this finding was approved as interface hepatitis. Afterwards, different authors published new scoring methods in the literature. Examples of these scoring methods are Scheuer, French METAVIR group, Kenneth Batts and Jurgen Ludwig scoring systems 1, 3, 13 .
The most important problem in evaluation of different histological activity scoring systems in CVH is intraobserver and interobserver variation [14] [15] [16] [17] . Common feature of the studies in the literature is the low interobserver and intraobserver error rate in staging; but this rate declines when scoring systems become more difficult to apply. The most important factors that can affect these studies are the experience of specialist, the qualitative and quantitative characteristics of the specimen and microscopy application techniques at low and high magnification 14, 18, 19 . Another example of problems in scoring is total score in Modified Knodell scoring system. For the reason that these total score is given via four different parameters, these values may not represent the severity of disease. For example, Modified HAI score 9 in two different patients may not consist of the same parameter scores or the course may not be the same.
METAVIR scoring system is presented in the literature as the scoring system experienced by interobserver compatibility rather than persons'own experiences between scoring systems 1, 20, 21 . Most widely used in Europe, this is an algorithmic approach system rather than simple scoring system as Modified Knodell system. There are important articles with different comments on all scoring systems in the literature [21] [22] [23] [24] [25] [26] [27] [28] .
For antiviral therapy, lamivudine and/or nucleos (t) ide analogue drugs were used in CHB cases of our study. We accepted treatment success as the sole criterion and did not separate our patients into groups according to the drugs used. In general, studies in the literature analyzed treatment response in therapy groups which used certain medicines. The main goal in many of these studies is to determine appropriate therapy and medicine protocol (industrial result). Our starting point in this study is to determine morphologic criteria affecting patient therapy (academic benefit) far from industry.
There is hardly any study in the literature investigating relation between treatment response and parameters constituting score rather than relation with the total score. Such studies may allow to revision or simplification of scoring systems. We tried to assess parametric approach in the foreground rather than total scoring system.
Discussion
The first classification of chronic hepatitis was described by De Groote J et al. in 1968 7 . Then, the specification of viral factors, increase in diagnosis and treatment options gave birth to the necessity of new classifications. According to the scoring system proposed by Knodell et al. evaluation was made by 4 categories and then degree gained by the collected points was defined as hepatic activity index (HAI) 8 , However, combined evaluation of fibrosis (stage) and inflammatory changes (grade), combined evaluation of two parameters (periportal inflammation and bridging necrosis) with different pathogenesis [9] [10] [11] , furthermore mathematical problems related to nonsuccessive sequence in scoring system time to time posed a problem for pathologists. Then Ishak et al. accepted confluent necrosis as the fourth criterion in necroinflammatory evaluation and stage has started to be defined separately 2 . Hepatocyte damage seen in "piecemeal necrosis" is There are many studies in the English literature investigating predictive factors for treatment response in CHB. The common point in these publications 29, 30 is the evaluation of morphological improvement criteria is performed according to the Knodell Scoring system. This scoring system is not in use today. Furthermore, the two point drop in control biopsies were taken as the criterion for improvement. Considering the interobserver or intraobserver compliance variation, we have doubt about the sufficiency of these two points as a parameter of treatment response. Another feature to note here is that cases had been evaluated by one pathologist and evaluation of control biopsies after treatment was performed after a certain time from the first biopsy so interobserver variation is inevitable. In our own study, for eliminating the interobserver or intraobserver compliance variation treatment success parameter had been generated out of clinical parameters.
Another study investigating predictive factors in CHB is performed by Shindo M et al. In this study, fibrosis was selected as the histopathologic parameter. Morphological grading was performed according to Knodell classification (excluding fibrosis) and fibrosis evaluation (staging) according to 5 point system. In multivariate analysis, high grade and low fibrosis were identified as important predictive factors for treatment response. The treatment response was better in low fibrosis stage in interferon-treated patients. In addition, in these patients necroinflammatory activity was seen as an important factor. There was no difference in terms of treatment response between stage 1-2 and stage 3-4 in lamivudin-treated patients 31 .
In our study three scoring systems commonly used in the world was compared with clinical treatment success regardless of drugs used for antiviral treatment. Only METAVIR lobular activity and total grade have relation with treatment response (p <0.05) in CHB; treatment success rate increases as lobular activity and total grade increase. This finding supports treatment indication in cases with higher histological grade. However, there is not enough information about this in the English literature. Generally, studies have been based on the Knodell or Modified Knodell system. Unlike our application (as noted above in our department and in our country we apply Modified Knodell scoring system), METAVIR system is more meaningful in clinicopathologic evaluation.
In our department we use Modified Knodell scoring system due to therapy planning of CHB according to reimbursement system by Social Security Institution of Turkish Republic. Evaluating biopsies according to this system we see that confluent necrosis parameter constituting an important point (6 points) in the system, impact the histopathological score negatively due to its descriptive rather than qualitative nature. It's known that this type of necrosis is a finding frequently seen in acute/subacute or autoimmune hepatitis rather than CVH 25 . Confluent necrosis was not seen in any patient neither in our current study nor in the studies known in the literature 15, 19 or seen in a few (1/363 cases) 1 . So, confluent necrosis was ignored by us. Albeit confluent necrosis is a parameter of scoring system, our own experience showed it's useless in evaluation of CVHs. Looking from this point of view, it's seen that Modified Knodell total HAI score automatically drops from 18 to 12. However in this way Modified Knodell scoring system becomes more feasible in terms of intraobserver and interobserver studies. We believe that removal of confluent necrosis which is seen infrequently in CVH from current scoring system or using scoring systems not including confluent necrosis in the routine practice will be more appropriate. At the national level, therapy planning according to activity index leads to the formation of an untreated patient group. Because decision of therapy starting at Modified Knodell HAI score 7 is admitted on the basis of total score of 18. Author's own experience is that the rarity of confluent necrosis may preclude some patients from the therapy who may benefit and this arbitrary cut-offs dictated by government or insurance agencies may leave out some candidates for good response. Exclusion of confluent necrosis from scoring system drops total score to 12 and so necessitates lowering of the treatment starting score. This problem does not create any important change in the staging evaluation.
In staging studies comparing two different fibrosis (staging) classification systems proposed by Knodell and Scheuer, reproducibility is higher in the simpler staging method as Scheuer fibrosis evaluation 15 . The point to be taken into account is that reproducibility of staging in Modified Knodell scoring system is low but it has more descriptive information 25 and application simplicity. In general, the more complex systems have the capability to provide more information than simple ones but are less reproducible 25 . In conjuction with interobserver agreement problems in current staging systems we have to know that 7 point (Modified Finally, we know that pretreatment histological assessment is important for treatment planning in CHB. We think that routinely applied Modified Knodell system will create more problems than METAVIR system. In this study it was seen that METAVIR scoring system is more adequate than Modified Knodell system in treatment decision making in CHB, and staging used for treatment planning is not a predictive factor.
